Wall Street brokerages forecast that Agenus Inc. (NASDAQ:AGEN – Get Rating) will post earnings per share (EPS) of ($0.27) for the current quarter, according to Zacks. Three analysts have provided estimates for Agenus’ earnings. The lowest EPS estimate is ($0.30) and the highest is ($0.23). Agenus posted earnings of ($0.37) per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 27%. The firm is expected to issue its next quarterly earnings results on Monday, January 1st.
On average, analysts expect that Agenus will report full-year earnings of ($1.09) per share for the current year, with EPS estimates ranging from ($1.20) to ($1.01). For the next financial year, analysts expect that the business will post earnings of ($0.83) per share, with EPS estimates ranging from ($1.22) to ($0.52). Zacks’ EPS calculations are a mean average based on a survey of analysts that that provide coverage for Agenus.
Agenus (NASDAQ:AGEN – Get Rating) last announced its quarterly earnings results on Tuesday, May 10th. The biotechnology company reported ($0.19) EPS for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.11. During the same period in the prior year, the firm earned ($0.27) earnings per share.
Several institutional investors and hedge funds have recently modified their holdings of AGEN. Advisor Group Holdings Inc. lifted its position in Agenus by 12.7% in the 3rd quarter. Advisor Group Holdings Inc. now owns 29,849 shares of the biotechnology company’s stock valued at $158,000 after acquiring an additional 3,370 shares in the last quarter. Leisure Capital Management lifted its position in shares of Agenus by 39.2% during the 4th quarter. Leisure Capital Management now owns 15,763 shares of the biotechnology company’s stock worth $51,000 after buying an additional 4,438 shares in the last quarter. Nations Financial Group Inc. IA ADV lifted its position in shares of Agenus by 42.8% during the 4th quarter. Nations Financial Group Inc. IA ADV now owns 15,016 shares of the biotechnology company’s stock worth $48,000 after buying an additional 4,500 shares in the last quarter. Arizona State Retirement System lifted its position in shares of Agenus by 10.3% during the 3rd quarter. Arizona State Retirement System now owns 48,473 shares of the biotechnology company’s stock worth $254,000 after buying an additional 4,538 shares in the last quarter. Finally, The Manufacturers Life Insurance Company lifted its position in shares of Agenus by 4.4% during the 4th quarter. The Manufacturers Life Insurance Company now owns 110,091 shares of the biotechnology company’s stock worth $354,000 after buying an additional 4,679 shares in the last quarter. Institutional investors own 65.88% of the company’s stock.
Shares of AGEN traded up $0.04 on Thursday, hitting $1.55. The company’s stock had a trading volume of 8,782,729 shares, compared to its average volume of 4,253,182. The company has a quick ratio of 2.12, a current ratio of 2.12 and a debt-to-equity ratio of 0.27. The firm’s fifty day moving average price is $2.41 and its 200-day moving average price is $2.91. Agenus has a fifty-two week low of $1.48 and a fifty-two week high of $6.79. The firm has a market capitalization of $418.92 million, a price-to-earnings ratio of -8.61 and a beta of 1.26.
About Agenus (Get Rating)
Agenus Inc, a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.
- Get a free copy of the StockNews.com research report on Agenus (AGEN)
- Carvana Insiders Buy Shares But Maybe You Shouldn’t
- Dutch Bros Gets Scalded By Inflation
- The S&P 500 Could Fall Another 28%
- Corning Stock is a Technology Value Play
- Wolverine Worldwide Is Ready To Rebound
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.